Director/PDMR Shareholding

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

37,221 (Deferred)

£0.00

24,815 (Matching)

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

62,036

£0.00

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.614

17,523 (Deferred)

£16.614

11,680 (Matching)

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

29,203

£16.614

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

19,375 (Deferred)

£0.00

12,917 (Matching)

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

32,292

£0.00

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.714

9,120 (Deferred)

£16.714

6,081 (Matching)

d)

Aggregated information

Aggregated volume Price

15,201

£16.714

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

12,243 (Deferred)

£0.00

8,163 (Matching)

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

20,406

£0.00

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.678

5,770 (Deferred)

£16.678

3,846 (Matching)

d)

Aggregated information

Aggregated volume Price

9,616

£16.678

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities on the vesting of awards under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.544

3,467 (Deferred)

$43.544

2,423 (Matching)

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

5,890

$43.544

e)

Date of the transaction

2020-02-18

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

15,407 (Deferred)

£0.00

10,273 (Matching)

d)

Aggregated information

Aggregated volume Price

25,680

£0.00

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.629

7,261 (Deferred)

£16.629

4,840 (Matching)

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

12,101

£16.629

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

7,302 (Deferred)

£0.00

4,869 (Matching)

d)

Aggregated information

Aggregated volume Price

12,171

£0.00

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.623

3,442 (Deferred)

£16.623

2,294 (Matching)

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

5,736

£16.623

e)

Date of the transaction

2020-02-17

f)

Place of the transaction

London Stock Exchange (XLON)